Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08FHZ
|
|||
Former ID |
DIB003550
|
|||
Drug Name |
ATL-313
|
|||
Synonyms |
DE-112; ATL-313 (ocular disease), Adenosine Therapeutics; ATL-313 (ocular disease), Clinical Data
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Arteriosclerosis [ICD-11: BD40; ICD-9: 440] | Phase 1/2 | [1], [2] | |
Company |
University of Virginia
|
|||
Structure |
Download2D MOL |
|||
Formula |
C23H29N7O6
|
|||
Canonical SMILES |
COC(=O)N1CCC(CC1)CC#CC2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)C(=O)NC5CC5)O)O)N
|
|||
InChI |
1S/C23H29N7O6/c1-35-23(34)29-9-7-12(8-10-29)3-2-4-14-27-19(24)15-20(28-14)30(11-25-15)22-17(32)16(31)18(36-22)21(33)26-13-5-6-13/h11-13,16-18,22,31-32H,3,5-10H2,1H3,(H,26,33)(H2,24,27,28)/t16-,17+,18-,22+/m0/s1
|
|||
InChIKey |
SQJXTUJMBYVDBB-RQXXJAGISA-N
|
|||
CAS Number |
CAS 844873-47-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adenosine A2a receptor (ADORA2A) | Target Info | Agonist | [3] |
KEGG Pathway | Rap1 signaling pathway | |||
Calcium signaling pathway | ||||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Vascular smooth muscle contraction | ||||
Parkinson's disease | ||||
Alcoholism | ||||
Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | |||
Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
Reactome | NGF-independant TRKA activation | |||
Adenosine P1 receptors | ||||
G alpha (s) signalling events | ||||
Surfactant metabolism | ||||
WikiPathways | Nucleotide GPCRs | |||
Monoamine Transport | ||||
GPCRs, Class A Rhodopsin-like | ||||
NGF signalling via TRKA from the plasma membrane | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5594). | |||
REF 2 | ClinicalTrials.gov (NCT01279083) Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension. U.S. National Institutes of Health. | |||
REF 3 | Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect Immun. 2006 May;74(5):2606-12. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.